IL187949A0 - Diastereomeric purification of rosuvastatin - Google Patents
Diastereomeric purification of rosuvastatinInfo
- Publication number
- IL187949A0 IL187949A0 IL187949A IL18794907A IL187949A0 IL 187949 A0 IL187949 A0 IL 187949A0 IL 187949 A IL187949 A IL 187949A IL 18794907 A IL18794907 A IL 18794907A IL 187949 A0 IL187949 A0 IL 187949A0
- Authority
- IL
- Israel
- Prior art keywords
- rosuvastatin
- diastereomeric
- purification
- diastereomeric purification
- Prior art date
Links
- 238000000746 purification Methods 0.000 title 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title 1
- 229960000672 rosuvastatin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72349105P | 2005-10-03 | 2005-10-03 | |
| US73297905P | 2005-11-02 | 2005-11-02 | |
| PCT/US2006/035711 WO2007040940A1 (en) | 2005-10-03 | 2006-09-12 | Diastereomeric purification of rosuvastatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL187949A0 true IL187949A0 (en) | 2008-03-20 |
Family
ID=37731511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL187949A IL187949A0 (en) | 2005-10-03 | 2007-12-06 | Diastereomeric purification of rosuvastatin |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20090187026A1 (OSRAM) |
| EP (1) | EP1817293A1 (OSRAM) |
| JP (1) | JP2008526897A (OSRAM) |
| KR (2) | KR101019450B1 (OSRAM) |
| BR (1) | BRPI0606170A2 (OSRAM) |
| CA (1) | CA2624801A1 (OSRAM) |
| IL (1) | IL187949A0 (OSRAM) |
| TW (1) | TW200804305A (OSRAM) |
| WO (1) | WO2007040940A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7851624B2 (en) | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
| US8455640B2 (en) | 2006-05-03 | 2013-06-04 | Msn Laboratories Limited | Process for statins and its pharmaceutically acceptable salts thereof |
| US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| WO2008053334A2 (en) * | 2006-10-31 | 2008-05-08 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin calcium |
| EP2125754B1 (en) * | 2007-02-08 | 2012-04-11 | Aurobindo Pharma Limited | Process for preparation of rosuvastatin calcium |
| US20090069563A1 (en) | 2007-07-12 | 2009-03-12 | Valerie Niddam-Hildesheim | Rosuvastatin intermediates and their preparation |
| EP2022784A1 (en) * | 2007-08-08 | 2009-02-11 | LEK Pharmaceuticals D.D. | Process for the preparation of methyl ester of rosuvastatin |
| WO2009143776A1 (zh) * | 2008-05-27 | 2009-12-03 | 常州制药厂有限公司 | 瑞舒伐他汀钙盐的制备方法及其中间体 |
| WO2010035284A2 (en) * | 2008-09-26 | 2010-04-01 | Matrix Laboratories Ltd | An improved process for the preparation of rosuvastatin calcium |
| EP2387561A4 (en) | 2009-01-19 | 2012-07-25 | Msn Lab Ltd | IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
| EP2467363A1 (en) | 2009-08-17 | 2012-06-27 | Aurobindo Pharma Limited | Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester |
| EP2526099B1 (en) | 2010-01-18 | 2016-03-30 | MSN Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| EP2383260A3 (en) * | 2010-04-30 | 2011-12-28 | Dipharma Francis S.r.l. | Process for the preparation of statins |
| ITMI20100753A1 (it) * | 2010-04-30 | 2011-10-31 | Dipharma Francis Srl | Procedimento per la preparazione di statine |
| HU230987B1 (hu) * | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
| CN104230817B (zh) * | 2013-06-19 | 2016-09-14 | 南京欧信医药技术有限公司 | 3，5-二羟基庚-6-烯酸衍生物的制备方法 |
| CN109580789B (zh) * | 2017-09-28 | 2021-06-22 | 安徽省庆云医药股份有限公司 | 一种液相色谱法分离测定瑞舒伐他汀叔丁酯及其光学异构体的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189164A (en) * | 1989-05-22 | 1993-02-23 | Sandoz Ltd. | Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US5218138A (en) * | 1992-09-02 | 1993-06-08 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds |
| JPH08301864A (ja) * | 1995-05-09 | 1996-11-19 | Toyobo Co Ltd | α−オキシ酸の分子間環状ジエステルの精製方法 |
| US5741934A (en) * | 1996-04-10 | 1998-04-21 | Sandler; Stanley R. | Preparation of primary mercaptans |
| DE19841342A1 (de) * | 1998-09-10 | 2000-04-20 | Merck Patent Gmbh | Neue Reaktivsysteme aus polymerisierbaren Monomeren , die Peroxide und stabilisierten Boralkylverbindungen enthalten |
| JP4565208B2 (ja) * | 2000-03-31 | 2010-10-20 | 株式会社クレハ | グリコリドの精製方法 |
| KR100511533B1 (ko) * | 2002-04-09 | 2005-08-31 | 임광민 | 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법 |
| BR0311195A (pt) * | 2002-05-21 | 2005-02-22 | Ranbaxy Lab Ltd | Processo de preparação de rosuvastatina |
| JP2004277396A (ja) * | 2003-01-23 | 2004-10-07 | Teijin Chem Ltd | 芳香族ポリカーボネートから芳香族ジヒドロキシ化合物と炭酸ジアルキルを得る方法 |
| WO2004103977A2 (en) * | 2003-05-21 | 2004-12-02 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of pyrimidine derivatives |
| WO2005023778A2 (en) * | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| EP1678148A1 (en) * | 2003-10-22 | 2006-07-12 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
| KR20090010126A (ko) * | 2003-12-24 | 2009-01-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 ｓｙｎ형 대 ａｎｔｉ형 비율을 지닌 스타틴의 제조 방법 |
| US20070179166A1 (en) * | 2003-12-24 | 2007-08-02 | Valerie Niddam-Hildesheim | Process for preparation of statins with high syn to anti ratio |
| US7851624B2 (en) * | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
| EP1673351A1 (en) * | 2004-07-13 | 2006-06-28 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
-
2006
- 2006-09-12 KR KR1020077012477A patent/KR101019450B1/ko not_active Expired - Fee Related
- 2006-09-12 EP EP06790220A patent/EP1817293A1/en not_active Withdrawn
- 2006-09-12 CA CA002624801A patent/CA2624801A1/en not_active Abandoned
- 2006-09-12 JP JP2007550593A patent/JP2008526897A/ja not_active Withdrawn
- 2006-09-12 BR BRPI0606170-2A patent/BRPI0606170A2/pt not_active IP Right Cessation
- 2006-09-12 WO PCT/US2006/035711 patent/WO2007040940A1/en not_active Ceased
- 2006-09-12 TW TW095133788A patent/TW200804305A/zh unknown
- 2006-09-12 KR KR1020097020950A patent/KR20090113920A/ko not_active Abandoned
-
2007
- 2007-12-06 IL IL187949A patent/IL187949A0/en unknown
-
2009
- 2009-02-26 US US12/380,419 patent/US20090187026A1/en not_active Abandoned
-
2010
- 2010-02-02 US US12/698,871 patent/US20100197916A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200804305A (en) | 2008-01-16 |
| WO2007040940A1 (en) | 2007-04-12 |
| JP2008526897A (ja) | 2008-07-24 |
| US20090187026A1 (en) | 2009-07-23 |
| BRPI0606170A2 (pt) | 2009-06-02 |
| US20100197916A1 (en) | 2010-08-05 |
| KR20070085667A (ko) | 2007-08-27 |
| KR20090113920A (ko) | 2009-11-02 |
| CA2624801A1 (en) | 2007-04-12 |
| KR101019450B1 (ko) | 2011-03-07 |
| EP1817293A1 (en) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL187949A0 (en) | Diastereomeric purification of rosuvastatin | |
| IL277406A (en) | A new use for IL-1 beta compounds | |
| IL185077A0 (en) | Purification of rapamycin | |
| IL185747A0 (en) | Use of supplemental assignments | |
| IL184036A0 (en) | Preparation of rosuvastatin | |
| SI2457905T1 (sl) | Postopki sinteze in/ali čiščenja diaminofenotiazinijevih spojin | |
| IL185757A0 (en) | Methods of decreasing calcifcation | |
| EP1970024A4 (en) | SYSTEM OF FULLY ADJUSTABLE LATCHES | |
| ZA200802893B (en) | Purification of water | |
| DK2392335T3 (en) | Use of 24-norUDCA | |
| GB0518508D0 (en) | Treatment of waste | |
| GB2431154B (en) | Purification treatment of water | |
| IL184570A0 (en) | Purification of oligonucleotides | |
| GB2432157B (en) | Letrozole purification process | |
| IL187948A0 (en) | Preparation of rosuvastatin | |
| GB0504333D0 (en) | Treatment of cytokine dysregulation | |
| GB0506164D0 (en) | Purification of salts | |
| GB0512574D0 (en) | Uses of (s)-clenbuterol | |
| GB0518003D0 (en) | Treatment of hepatatis c | |
| GB0510013D0 (en) | Interaction of SNEV | |
| GB2445888B (en) | Treatment of hypertension | |
| GB0508200D0 (en) | Purification of nanostructures | |
| AU158102S (en) | Purification unit | |
| HK1108286A (en) | Purification of oligonucleotides | |
| ZA200802876B (en) | Novel use of IL-1beta compounds |